<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>From 1987 to 1995, 22 children with refractory <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> entered a phase II study of high-dose thiotepa (HDT) (900 mg/m2) followed by stem cell transplantation (SCT) in the Pediatrics Department of the Institut Gustave Roussy </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> types were <z:hpo ids='HP_0002859'>rhabdomyosarcoma</z:hpo> (eight), <z:hpo ids='HP_0002669'>osteosarcoma</z:hpo> (seven), <z:hpo ids='HP_0003006'>neuroblastoma</z:hpo> (three), Ewing's <z:hpo ids='HP_0100242'>sarcoma</z:hpo> (three) and Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (one) </plain></SENT>
<SENT sid="2" pm="."><plain>Before HDT, <z:hpo ids='HP_0000001'>all</z:hpo> had been extensively treated with conventional chemotherapy, surgical resection of the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> (13/22) and of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> (6/22), and radiotherapy of the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> in three patients </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> had <z:e sem="disease" ids="C1513041" disease_type="Disease or Syndrome" abbrv="">measurable disease</z:e>, at the site of the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> (3 patients), of the <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> (9 patients) or both (10 patients) </plain></SENT>
<SENT sid="4" pm="."><plain>Toxicity from the HDT was severe but acceptable </plain></SENT>
<SENT sid="5" pm="."><plain>No toxicity-related <z:hpo ids='HP_0011420'>death</z:hpo> occurred </plain></SENT>
<SENT sid="6" pm="."><plain>The median duration of <z:hpo ids='HP_0001875'>neutropenia</z:hpo> and <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> was 18 days (5-37) and 30 days (7-377), respectively </plain></SENT>
<SENT sid="7" pm="."><plain><z:mpath ids='MPATH_681'>Septicemia</z:mpath> was documented in four patients </plain></SENT>
<SENT sid="8" pm="."><plain>Severe <z:hpo ids='HP_0002014'>diarrhea</z:hpo> was observed in seven patients </plain></SENT>
<SENT sid="9" pm="."><plain>Mild hepatic toxicity occurred 18 times </plain></SENT>
<SENT sid="10" pm="."><plain>No CR and 11/22 PR were documented: <z:hpo ids='HP_0002669'>osteosarcoma</z:hpo> 4/7, <z:hpo ids='HP_0002859'>rhabdomyosarcoma</z:hpo> 4/8, Ewing's <z:hpo ids='HP_0100242'>sarcoma</z:hpo> 2/3; 1/1 Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> progressed </plain></SENT>
<SENT sid="11" pm="."><plain>We conclude that at a dose of 900 mg/m2 followed by SCT support in these heavily pretreated children, the main toxicity induced by thiotepa was digestive </plain></SENT>
<SENT sid="12" pm="."><plain>The response rate observed, especially in <z:hpo ids='HP_0100242'>sarcoma</z:hpo>, is particularly encouraging </plain></SENT>
<SENT sid="13" pm="."><plain>Thiotepa should be further evaluated in HDC regimens either in combination with other <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> or in rapidly cycled courses of HDC with SCT </plain></SENT>
</text></document>